🇺🇸 FDA
Patent

US 7772239

Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists

granted A61KA61K31/46A61K31/496

Quick answer

US patent 7772239 (Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists) held by Theravance, Inc. expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/46, A61K31/496, A61P, A61P1/00